Akarna Therapeutics Secures $15,000,000 Series B Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=2c23beed-fc6a-4737-be25-32c4af28f6f6
Date
2/17/2016
Company Name
Akarna Therapeutics
Mailing Address
1012 Second Street Encinitas, CA 92007 USA
Company Description
Akarna Therapeutics is a biopharmaceutical company developing novel small molecule therapeutics that target inflammatory and fibrotic diseases for which there is no approved treatment.
Website
http://www.akarna.com
Transaction Type
Venture Equity
Transaction Amount
$15,000,000
Transaction Round
Series B
Proceeds Purposes
Akarna will use the funds to accelerate the development of its lead FXR agonist drug candidate through human proof-of-concept studies in patients with non-alcoholic steatohepatitis (NASH), a progressive form of fatty-liver disease for which there are no approved therapies.
M&A Terms
Venture Investor
Forbion Capital Partners
Venture Investor
New Science Ventures
Venture Investor
Third Point